The Hyderabad-based drug company, Dr Reddy's Laboratories, will conduct the trial in India under a pact it had signed last month with Russia Direct Investment Fund, the Russian government's sovereign wealth fund which is promoting Sputnik V worldwide.
A US$60 (B1872) double-dose experimental coronavirus vaccine is being made available to some residents in an eastern Chinese city, health officials have said, the first details of a mass rollout for an as-yet unproven vaccine. Besides, the phase 3 clinical trial of the vaccine commenced in the UAE last week, the IANS report said.
The results came from a combined Phase 1 and Phase 2 trial involving more than 600 healthy adults conducted between April 29 and July 30. While Sputnik V is now undergoing Phase-3 clinical trials involving 40,000 volunteers in Russian Federation, a Phase-3 clinical trial of the vaccine has also commenced in the UAE last week.
"We are pleased to collaborate with the Indian regulators and in addition to Indian clinical trial data, we will provide safety and immunogenicity study from the Russian phase 3 clinical trial", said Kirill Dmitriev, chief executive officer of the Russian Direct Investment Fund after the renewed approval.
Currently, there are three vaccine candidates undergoing human trials in India.
Russian Federation became the first country to give approval to the vaccine but came in for criticism for going ahead with Sputnik V without a large-scale trial. The trial will take six months to complete.
Prime Minister Narendra Modi on Saturday called for full preparedness to ensure speedy access to COVID-19 vaccines for every citizen.
A National Expert Group on Vaccine Administration for Covid-19 (NEGVAC) has in consultation with state governments prepared a detailed blueprint for vaccine storage, distribution and administration.
'Since the start of the pandemic, specialist UK Government units have also been working rapidly to identify and rebut false information about coronavirus, including working closely with social media companies'. However, in a recent announcement by the Prime Minister's Office, the Centre said there is no major mutation in viral strain in India, implying that the vaccine development and its efficiency will not be impacted. The plan aims to cover over 23% of the population in the first phase and was discussed in a meeting of the group of ministers on Covid-19 headed by Union health minister Harsh Vardhan earlier this week.